ClinicalTrials.gg
Status unknownNCT05489276Updated Aug 5, 2022

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

A Phase 1 interventional study of TQB2825 injection in Hematological Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 148 studies in Hematologic Neoplasms with a site in China — 75 open to participants now, 83 under way, 8 of them phase 3. Hematologic Neoplasms · China.

Planned enrollment
24th of 123
180 · median 56
Started
2022
with 17 others
Phase 1
57 of 148
30 open now
Registered
60th of 148
by date

Among the 148 studies in Hematologic Neoplasms with a site in China, this one is the 24th largest by planned enrollment of the 123 interventional ones that give a count, is one of 18 that started in 2022, is one of 57 in phase 1, and was the 60th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

75 of the 148 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Hematologic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a single-group, open, dose escalation and expansion Phase I clinical study, with phase I being a dose escalation study and Phase II being a dose expansion study. The purpose of this study was to evaluate the safety and tolerability of TQB2825 injection in CD20-positive hematological tumor subjects, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) (if any), or optimal biological dose (OBD), and recommended phase II dose (RP2D).

03

Conditions studied

  • Hematological Tumors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Malignant hematologic tumors, including but not limited to lymphoma, leukemia, myeloma, etc., which are clearly diagnosed by histology or cytology (report of immunotyping results is required).
  • 2 Immunophenotypic analysis showed CD20 positive.
  • 3 18 years old ≤ Age ≤75 years old; (ECOG) performance status of 0 to 1; ≥ 3 months.
  • 4 Prior induction or salvage therapy ≥ treatment, adequate treatment with at least one regimen containing an anti-CD20 mab (combination chemotherapy or monotherapy), and meeting the following criteria:

    1. Patients who have not been alleviated after the last adequate treatment or whose disease has progressed after remission, or who have after hematopoietic stem cell transplantation (auto-HSCT)
    2. Patients with refractory Anti-CD20 monoclonal antibody.
  • 5 According to the 2014 Lugano criteria, there is at least one , that is, a lymph node lesion with a diameter >15 mm or an extranodal lesion with a diameter >10 mm according to the cross-sectional CT image (for tumors with the 2014 Lugano evaluation criteria).
  • 6 Negative serum/urine pregnancy test within 7 days prior to initial dosing and must be non-lactating subjects; Female subjects of reproductive age agree to use (such as an intrauterine device, birth control pill, or condom) during the study period and for six months after the study ends; Male subjects agreed to use contraception during the study period and for six months after the end of the study period.
  • 7 The subjects voluntarily joined the study and signed with good compliance.

Exclusion criteria

Exclusion Criteria:

  • 1 Tumor diseases and medical history:

    1. Hematologic that have or are suspected to involve the central nervous system (CNS) or primary CNS lymphoma;
    2. Subjects who had or currently had other malignancies within 3 years. Two conditions can be included in clinical trials: five consecutive years of disease-free survival (DFS) for other malignancies treated with a single operation; Cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)];
    3. uncontrolled pleural effusion ascites requiring repeated drainage and pericardial effusion with medium or higher volume.
  • 2 Previous anti-tumor therapy:

    1. Prior treatment with other antibodies targeting both CD3 and CD20;
    2. Received any antibody drug therapy, CAR T therapy, or other immunocytotherapy, or within 3 months prior to initial administration;
    3. Prior allogeneic hematopoietic stem cell transplantation (ALLO-HSCT);
    4. Any major surgery, chemotherapy and/or radiotherapy, immunotherapy or targeted therapy within 4 weeks prior to initial administration;
    5. The half-life of the first administration is less than 5 drugs from the previous oral targeted therapy (calculated from the end time of the last treatment);
    6. Received proprietary Chinese medicines with anticancer indications specified in NMPA approved drug instructions within 2 weeks prior to initial administration;
    7. The toxicity of previous antitumor treatment is not recovered to ≤ grade 1( 5.0) .
  • 3 Associated diseases and medical history:

    1. Liver abnormalities: decompensated cirrhosis and active hepatitis;
    2. Renal abnormalities:

      I. Renal failure requiring hemodialysis or peritoneal dialysis; II. Previous history of nephrotic syndrome.

    3. Gastrointestinal abnormalities:

      I. Chronic diarrhea persists despite maximum medical treatment; II. Presence of active inflammatory bowel disease within 4 weeks prior to initial administration.

    4. Cardiovascular and cerebrovascular abnormalities:

      I. With or prior history of central nervous system diseases; II. MRI evidence of brain inflammation and/or vasculitis; III. Occurrence of cerebrovascular accident or cerebral infarction within 6 months before the first administration; IV. Arteriovenous thrombosis events such as deep vein thrombosis and pulmonary embolism occurred within 3 months before the first administration; V. With or prior history of cardiovascular disease; VI. Hypertension that cannot be controlled by the combination of the two drugs (systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg measured at least twice); VII. Previous or current heart valvulitis or endocarditis.

    5. Medical history of immunodeficiency: known (HIV) infection, or other acquired, congenital immunodeficiency disease;
    6. Uncontrollable systemic bacterial, fungal or viral infection.
    7. Lung disease:

      I. Previous or present with or suspected (COPD) and forced expiratory volume at the end of 1 second () \<60% (estimated value); II. Past or present non-infectious pneumonia requiring treatment; IV. Active tuberculosis.

    8. History of severe allergies of unknown cause; Known allergy to monoclonal antibodies or to exogenous human immunoglobulin; Known allergy to investigational drug .
  • 4 Getting a within 4 weeks prior to initial administration or during planned study period.
  • 5 Participated in clinical trials of other drugs within 30 days.
  • 6 It is estimated that the compliance of patients participating in this clinical study is insufficient.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    TQB2825 injection

    TQB2825 injection is given intravenously every 2 weeks, and every 4 weeks (28 days) as a treatment cycle, with the longest treatment duration not exceeding 2 years.

    Drug: TQB2825 injection

Interventions

  • TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity(DLT)

    To evaluate DLT of TQB2825 injection in Chinese adult patients with CD20 positive hematological tumors.

    Time frame: 104 weeks

  2. the maximum tolerated dose (MTD)

    To evaluate MTD of TQB2825 injection in Chinese adult patients with CD20 positive hematological tumors.

    Time frame: 104 weeks

  3. Recommended Phase II Dose(RP2D)

    To evaluate RP2D of TQB2825 injection in Chinese adult patients with CD20 positive hematological tumors.

    Time frame: 104 weeks

Secondary outcomes

  1. Adverse events (AE)

    The occurrence of all adverse events (AE)

    Time frame: Baseline up to 104 weeks

  2. serious adverse events (SAE)

    serious adverse events (SAE)

    Time frame: Baseline up to 104 weeks

  3. treatment-related adverse events(TRAE)

    treatment-related adverse events(TRAE)

    Time frame: Baseline up to 104 weeks

  4. Elimination half-life (to be used in one-or non- compartmental model) (t1/2)

    t1/2 is time that takes for the blood concentration of TQB2825 or metabolite(s) to drop by half.

    Time frame: Assessments were performed at fixed time points from Cycle 1 to Cycle 6, with each period being 28 days, about 6 months

  5. Tmax

    Time to reach maximum (peak) plasma concentration following drug administration(Tmax)

    Time frame: Assessments were performed at fixed time points from Cycle 1 to Cycle 6, with each period being 28 days, about 6 months

  6. Maximum (peak) plasma drug concentration (Cmax)

    Cmax is the maximum plasma concentration of TQB2825.

    Time frame: Assessments were performed at fixed time points from Cycle 1 to Cycle 6, with each period being 28 days, about 6 months

  7. Area under the plasma concentration-time curve from time zero to time t (AUC0-t)

    To characterize the pharmacokinetics of TQB2825 by assessment of area under the plasma concentration time curve from the first dose to the last measurable concentration point.

    Time frame: Assessments were performed at fixed time points from Cycle 1 to Cycle 6, with each period being 28 days, about 6 months

  8. Area under the plasma concentration-time curve from time zero to time ∞(AUC0-∞)

    To characterize the pharmacokinetics of TQB2825 by assessment of area under the plasma concentration time curve from the first dose to infinity.

    Time frame: Assessments were performed at fixed time points from Cycle 1 to Cycle 6, with each period being 28 days, about 6 months

  9. Minimum steady-state plasma drug concentration during a dosage interval (Cmin,ss)

    Cmin is the minimum plasma concentration of TQB2825

    Time frame: Assessments were performed at fixed time points from Cycle 1 to Cycle 6, with each period being 28 days, about 6 months

  10. Progress Free Survival(PFS)

    Time from the first dose to the first documentation of PD or death from any cause, whichever occurs first

    Time frame: up to 96 weeks

  11. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  12. Duration of Response (DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 96 weeks

  13. Overall survival (OS)

    the time from start of study treatment to date of death due to any cause

    Time frame: up to 96 weeks

07

Study locations

1 of 1 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Oct 2023, 19 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 19 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Aug 5, 2022
StartActual
Mar 22, 2022
Primary completionEst.
Oct 2023
CompletionEst.
Dec 2023
Last update
Aug 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05489276
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Mar 22, 2022
Primary completion
Oct 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Aug 5, 2022

Study contacts

Yuqin Song, Master
Contact
SongYQ_VIP@163.com
010-88196118

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB2825

Start the discussion